CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Public ClinicalTrials.gov record NCT02900248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Registry participants with advanced malignancy or myelodysplasia will have a sample of their tumor or tissue analysed for genetic alterations using next generation sequencing (NGS) performed in a lab that has been certified to meet a high quality standard. Treatments and outcomes will be reported to the registry to allow further understanding of how genetic differences can lead to better diagnosis and treatments.
Study identification
- NCT ID
- NCT02900248
- Recruitment status
- Terminated
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 23 participants
Conditions and interventions
Conditions
- Neoplasms
- Lung Neoplasms
- Colon Neoplasms
- Breast Neoplasms
- Pancreatic Neoplasms
- Prostate Neoplasms
- Kidney Neoplasms
- Liver Neoplasms
- Rectal Neoplasms
- Hematologic Neoplasms
- Multiple Myeloma
- Myelodysplastic Syndromes
- Ovarian Neoplasms
- Bladder Neoplasms
- Testicular Neoplasms
- Endometrial Neoplasms
- Brain Neoplasms
- Biliary Tract Neoplasms
- Head and Neck Neoplasms
- Uterine Cervical Neoplasms
- Skin Neoplasms
- Melanoma
- Gastric Neoplasms
- Anal Neoplasms
- Sarcoma
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2017
- Primary completion
- Mar 28, 2019
- Completion
- Mar 28, 2019
- Last update posted
- Apr 1, 2019
2017 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teton Cancer Institute | Idaho Falls | Idaho | 83404 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02900248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 1, 2019 · Synced Sep 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02900248 live on ClinicalTrials.gov.